Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles

In cancer immunotherapy, therapeutic methods targeting NK are highly expected. NK cell-based therapy using NK-92, a human NK cell line, has been clinically evaluated. Delivering mRNA into NK-92 cells is a potent strategy for enhancing its functions. However, the use of lipid nanoparticles (LNP) for this purpose has not yet been evaluated. We previously developed a LNP that was composed of CL1H6 (CL1H6-LNP) for the efficient delivery of siRNA to NK-92 cells, and the use of this material for delivering mRNA to NK-92 cells is reported in this study. Compared with a DLin-MC3-DMA based LNP, used as a benchmark, the CL1H6-LNP caused a high mRNA expression intensity and a cell transfection efficiency of 100%. The efficient mRNA delivery by this CL1H6-LNP is attributed to the high affinity for NK-92 cells and the intense, rapid fusion with the endosomal membrane. It therefore appears that the CL1H6-LNP could be a useful non-viral vector for modifying the NK-92 functions by mRNA. Our findings also provide some insights into the design and development of LNPs for delivering mRNA to NK-92 and NK cells.

Automated summary

This study reports the use of CL1H6-LNP, a lipid nanoparticle, for delivering mRNA to NK-92 cells. Compared to the benchmark DLin-MC3-DMA based LNP, the CL1H6-LNP showed higher mRNA expression intensity and 100% cell transfection efficiency. The efficient mRNA delivery by CL1H6-LNP is attributed to its high affinity for NK-92 cells and rapid fusion with the endosomal membrane, highlighting its potential as a non-viral vector for modifying NK-92 cell functions.